Educational content only. Not medical advice, and no doctor-patient relationship is created. Read the medical disclaimer
Peptide extract
Thymalin
Also known as: Thymus peptide extract (calf thymus polypeptide complex)
A Russian calf-thymus peptide extract used since the 1980s as an immune corrector. Most evidence comes from small Russian studies; no large Western placebo-controlled trials exist.
Tier 3 · Education only
Grade C · Limited human evidence
Educational content only, not medical advice. Discussion here does not mean this therapy is prescribed by Youthful Medicine or available to you. Read the medical disclaimer
U.S. regulatory status
Not FDA-approved. FDA has named Thymalin products sold online as unapproved new drugs in warning letters. Registered in Russia and some CIS countries since the 1980s.
Not FDA-approved. FDA warning letters (for example to US Chem Labs, February 2024) list Thymalin sold online as an unapproved new drug in violation of the FD&C Act. It is not on the 503A bulks list and cannot be legally marketed in the U.S. as a drug. It is a registered medicine in Russia.
What it is
Thymalin is a complex of small peptides extracted from calf thymus, developed in the 1970s by Vladimir Khavinson and Vyacheslav Morozov at the Military Medical Academy in St. Petersburg. Russian researchers identify two dipeptides, KE (Lys-Glu) and EW (Glu-Trp, the active ingredient of Thymogen), as key active components. It is a mixture, not a single molecule, and it is different from thymosin alpha-1 (thymalfasin), a single 28-amino-acid synthetic peptide. In Russia it is classed as a peptide bioregulator and described as an immune corrector that normalizes rather than simply stimulates immune function.
How it is thought to work
Russian studies report that Thymalin supports the maturation of T cells, raises CD3, CD4 and CD8 counts in people with low levels, and improves natural killer cell activity and phagocytosis. In immune deficiency it is described as raising interferons and IL-2, and in inflammatory states as lowering TNF, IL-6 and IL-1 beta. A 2020 lab study found it influenced the differentiation of human blood-forming stem cells. The Khavinson school also proposes that its short peptides act on gene expression; this remains a hypothesis not confirmed in Western molecular studies.
The science, in depth
Thymalin was one of the first peptide bioregulators developed by the Khavinson school; later work separated out its short peptides, including Glu-Trp (Thymogen) and Lys-Glu. A 2023 study proposed that these dipeptides affect genes and proteins involved in COVID-19 inflammation. Animal studies report effects on bone marrow precursor cells, wound and bone repair, and tumor growth in rats. Thymalin vs thymosin alpha-1: much Western literature on thymic peptides concerns thymosin alpha-1, a different single molecule. Its large sepsis trial (TESTS, BMJ 2025) found no mortality benefit, a 2026 Cochrane review in hepatitis B rated the evidence very low certainty, a hepatitis C trial showed no benefit overall, and a melanoma trial showed more tumor responses with a non-significant survival trend. Another thymus extract, thymostimulin, showed no benefit in a phase III liver cancer trial. These results inform the class but cannot be applied directly to Thymalin.
Animations simplify biology for teaching. They are not a claim that this peptide works this way in people.
What the research shows
Most data come from Russian-language journals and monographs from 1974 onward: mostly small, open-label or cohort studies. Reported uses include recurrent and chronic infections (bronchitis, COPD flares, pyelonephritis, prostatitis, recurrent herpes, skin infections), support during chemotherapy and radiotherapy, surgery and wound recovery, and as an add-on in psoriasis, atopic dermatitis and rheumatoid arthritis. The best-known study, published by the product's developers, followed 266 older adults for 6 to 8 years and reported 2.0 to 2.1 times lower mortality with Thymalin and 2.0 to 2.4 times fewer acute respiratory illnesses versus control (Neuro Endocrinol Lett 2003); methods were thinly reported and the findings have not been independently replicated. During COVID-19, a Russian study in severe middle-aged and older patients reported hospital mortality of 20.6% with Thymalin added to standard care versus 40.9% with standard care alone (Adv Gerontol 2022); this was a retrospective review, so it shows an association and cannot prove Thymalin caused the difference. No placebo-controlled trial has confirmed mortality, cancer or longevity benefits.
Clinical trials to watch
No registered U.S. trials of Thymalin. What would matter: a modern randomized, placebo-controlled trial in older adults with measurable immune decline, using hard outcomes such as infections and hospitalizations. Related: a recruiting Phase 1 trial of thymosin alpha-1 as a vaccine-response enhancer in older adults (NCT06821100).
Safety and considerations
Generally reported as well tolerated. Common effects are injection-site pain and redness, mild fever or brief flu-like symptoms. Because it is made from cattle tissue, allergy to beef proteins is a contraindication and there is a theoretical risk of animal-borne infection. There are no controlled data in pregnancy, breastfeeding or children; the Russian label lists these, hypersensitivity, active autoimmune flare and organ transplant on immunosuppression as reasons to avoid it. It may counteract immunosuppressive medicines. Products sold in the U.S. are unregulated research chemicals with no FDA check of purity, potency or sterility.
Testing and monitoring
Thymalin is not approved in the U.S., so there is no U.S. monitoring standard. Russian practice checks immune markers before and after a course. Education only, not a treatment plan.
Before starting
Complete blood count with differential
Lymphocyte subsets (CD3, CD4, CD8) and immunoglobulins where available
Allergy history, especially to beef proteins
Review of autoimmune disease, transplant status, pregnancy and immunosuppressive medicines
During care
Repeat blood count and immune markers at intervals the physician chooses
Track infections, injection-site reactions and any change in autoimmune activity
Note that no validated marker of response exists in Western practice
Needs a physician’s attention
Allergic reaction, hives or swelling
Fever that persists beyond a day or two
New or worsening autoimmune symptoms
Any planned use with cancer treatment or immunosuppressants
Sources: Russian clinical practice as summarized in Dr. Tahir’s review notes; FDA warning letter, February 2024.
Educational only, not medical advice. These are the tests researchers and clinicians discuss, not a personal plan. A licensed physician should decide what to order, interpret your results, and manage any therapy. Do not start, stop, or change a treatment based on this page.
What this research could teach us
Thymalin raises a real question about immune aging: can restoring thymus signals in people with measurable T-cell decline reduce infections? It also shows the gap between decades of observational use and the controlled trials needed to prove benefit.
Our position
A historic Russian thymus extract with 40+ years of low-grade evidence for immune restoration in older adults and chronic infection. Interesting as the parent of Thymogen, but not proven by placebo-controlled trials. Education only.
Video lesson
Sources and further reading
Thymalin: Khavinson VKh, Morozov VG. Neuro Endocrinol Lett 2003;24(3-4):233-40 (PMID 14523363). Thymalin and hematopoietic stem cells, Bull Exp Biol Med 2020 (doi:10.1007/s10517-020-05016-z). Thymalin in COVID-19 complex therapy, Stem Cell Rev Rep 2021 (doi:10.1007/s12015-020-10087-6). Tocilizumab and Thymalin in severe COVID-19, Adv Gerontol 2022 (PMID 36169363). KE and EW dipeptides of Thymalin, Int J Mol Sci 2023 (doi:10.3390/ijms241713377). FDA warning letter to US Chem Labs, February 7, 2024. Related thymic peptides, for comparison only: Wu J, et al. TESTS, BMJ 2025 (doi:10.1136/bmj-2024-082583). Naing C, et al. Cochrane 2026 (doi:10.1002/14651858.CD014610.pub2). Ciancio A, et al. J Viral Hepat 2012 (doi:10.1111/j.1365-2893.2011.01524.x). Maio M, et al. J Clin Oncol 2010 (doi:10.1200/JCO.2009.25.5208). Dollinger MM, et al. BMC Cancer 2010 (doi:10.1186/1471-2407-10-457). Wolf E, et al. Cochrane 2011 (doi:10.1002/14651858.CD003993.pub3).
AT A GLANCE
Quadrant
Autoimmunity & Inflammation
Tier
Tier 3 · Education only
Evidence grade
Grade C · Limited human evidence
Last reviewed
Is this right for you?
Only a physician who has evaluated you can answer that. Consultations are with licensed Youthful Medicine providers.
OUR COMMITMENTS
Science forward
Every claim graded, dated and sourced to primary research.
Patient safety first
No dosing online, no research chemicals, and only licensed pharmacies.
Professional collaboration
We work alongside your physicians and welcome research partners.
Never use products labeled “research use only” or “not for human use.” Purity, dose and sterility are unverified.